Drosomycin-2

Drosomycin, the first inducible antifungal peptide isolated from Drosophila, belongs to the superfamily of CSalphabeta-type defensins. In the present study we report a modified approach for high-level expression of drosomycin, which allows us to evaluate its differential potency on the filamentous fungus Neurospora crassa WT (wild type) and N. crassa MUT16, a specific resistance mutant strain to plant defensins, by using different approaches. The results presented here show for the first time that N. crassa MUT16 is resistant to our recombinant drosomycin. Differential survival rates of Drosophila larvae infected by N. crassa WT and MUT16 further confirm the key antifungal role of drosomycin in vivo. The absence of activity against MUT16 suggests a mechanical commonality between drosomycin and plant defensins, which provides additional evidence in favor of their homologous relationship. Furthermore, the existence of drosomycin-like molecules in fungi suggests that all these peptides could originate from a common ancestry rather than horizontal gene transfer between plants and insects, which is further strengthened by the monophyletic origin of these peptides from plants, fungi and insects.

Drosomycin is an inducible antifungal peptide of 44 residues initially isolated from bacteria-challenged Drosophila melanogaster. The systemic expression of drosomycin is regulated by the Toll pathway present in fat body, whereas inducible local expression in the respiratory tract is controlled by the Immune Deficiency (IMD) pathway. Drosomycin belongs to the cysteine-stabilized alpha-helical and beta-sheet (CSalphabeta) superfamily and is composed of an alpha-helix and a three-stranded beta-sheet stabilized by four disulphide bridges. Drosomycin exhibits a narrow antimicrobial spectrum and is only active against some filamentous fungi. However, recent work using recombinant drosomycin expressed in Escherichia coli revealed its antiparasitic and anti-yeast activities. Two evolutionary epitopes (alpha- and gamma-patch) and the m-loop have been proposed as putative functional regions of drosomycin for interaction with fungi and parasites, respectively. Similarity in sequence, structure and biological activity suggests that drosomycin and some defensin molecules from plants and fungi could originate from a common ancestor.

Drosomycin (Drs) gene encodes a 44-residue inducible antifungal peptide, Drosomycin, in Drosophila melanogaster. Six genes, Drs-lC, Drs-lD, Drs-lE, Drs-lF, Drs-lG and Drs-lI, show homology to the Drs form in a multigene family on the 3rd chromosome of D. melanogaster. It is the first experimental demonstration that the six members in the Drs family act as functional genes. To further delineate the functional divergence of these six members, their cDNA sequences were cloned respectively into the pET-3C vector and expressed in the E. coli. The antifungal activity of the expression products was assayed using the Cerletti's method. The results showed a difference among the six isoforms in antifungal activity against the tested fungal strains: in which Drs was most effective and showed antifungal activity to all seven fungal strains, whereas isoform Drs-lC was effective to six strains, Drs-lD was effective to five strains, Drs-lG was effective to four strains, and Drs-lE and Drs-lF were effective to only three strains. Drs-lI had no activity against any tested fungal strains. By comparing the variable residue sites of these six isoforms to that of Drosomycin in the three-dimensional structure, we suggested that the reduction in the antifungal activity was due to the variable residues that were not in the alpha-helix. In addition, two inserted residues (RV) in Drs-lI may affect the dimensional structure and resulted in a functional change. These results may explain the evolution of the Drosomycin multigene family and its functional divergence.